Search

In order to obtain the novel poly(ε-caprolactone) (PCL) cross-linked networks with good shape memory properties, the cross-linked networks of PCL with different molecular weights were prepared by thiol-ene click chemistry method, and its microstructure, thermal properties, mechanical properties and shape memory properties were characterized. The results show that the hydroxyl end of PCL was successfully converted to acrylate-terminated PCL, and almost all the samples show perfect cross-linked network, and the cross-linked polymer has a thermally induced shape memory effect; with the increase of the molecular weight of PCL diol, the melting temperature and crystallinity of the cross-linked network also show an upward trend; the molecular weight of PCL diol has a certain influence on its fixation ability, but regardless of the length of PCL diol, the shape recovery rate of all samples can reach more than 90%. The efficient thiol-ene click chemistry reaction ensures the uniform distribution of PCL chains between cross-linked nodes, the cross-linked network has good network structure, good mechanical and shape memory properties. The exploration of new PCL cross-linked network provides a feasible way for the end functionalization of polymers.

Objective To explore the impact of venous thromboembolism (VTE) on the diagnosis and treatment of lung cancer patients. Methods We retrospectively analyzed the clinical data of lung cancer patients with VTE treated in Peking University Cancer Hospital. The incidence of VTE was calculated and the relation between VTE and lung cancer was analyzed. Results Among 1766 patients with lung cancer, VTE occurred in 115(6.5%) patients. Among 115 VTE cases, there were 78(67.8%) males patients; 82(71.3%) cases were deep venous thrombosis, 21(18.3%) cases were pulmonary embolism, 12(10.4%) cases were deep venous thrombosis with pulmonary embolism; 74(64.3%) cases were symptomatic VTE; 102(88.7%) patients received antithrombotic therapy. Among the patients who received antithrombotic therapy, 97(95.1%) cases chose drug therapy. In drug treatment, 65(67.0%) cases used adequate/standard dose. Among 115 VTE cases, 52(45.2%) patients had improvement or disappearance of thrombus, 32(27.8%) patients had no improvement, and 31(27.0%) patients with unknown results; 11(9.6%) patients had adverse reactions such as bleeding during antithrombotic therapy; 30(26.1%) patients changed antineoplastic treatment plan due to VTE. Conclusion VTE is a common complication of lung cancer patients. Antithrombotic therapy for lung cancer patients with VTE is complex, the treatment effect is not ideal and the risk of adverse reactions such as bleeding is high. VTE has a great impact on the implementation of anti-cancer treatment.

Background: Radiotherapy combined with chemotherapy or molecular targeted therapy remains the standard of treatment for brain metastases from non-small cell lung cancer (NSCLC). The aim of this study is to determine if the deferral of brain radiotherapy impacts patient outcomes., Methods: Between May 2003 and December 2015, a total of 198 patients with brain metastases from NSCLC who received both brain radiotherapy and systemic therapy (chemotherapy or targeted therapy) were identified. The rate of grade 3-4 adverse reactions related to chemotherapy and radiotherapy had no significant difference between two groups. 127 patients received concurrent brain radiotherapy and systemic therapy, and 71 patients received deferred brain radiotherapy after at least two cycles of chemotherapy or targeted therapy. Disease specific-graded prognostic assessment was similar in early radiotherapy group and deferred radiotherapy group., Results: Median overall survival (OS) was longer in early radiotherapy group compared to deferred radiotherapy group (17.9 months vs 12.6 months; P=0.038). Progression free survival (PFS) was also improved in patients receiving early radiotherapy compared to those receiving deferred radiotherapy (4.0 months vs 3.0 months; P<0.01). Receiving tyrosine kinase inhibitor (TKI) therapy after the diagnosis of brain metastases as any line therapy improved the OS (20.0 months vs 10.7 months; P<0.01), whereas receiving TKI as first line therapy did not (17.9 months vs 15.2 months; P=0.289)., Conclusions: Our study suggests that the use of deferred brain radiotherapy may resulted in inferior OS in patients with NSCLC who develop brain metastases. A prospective multi-central randomized study is imminently needed.

Background and Objective: Chemotherapy is a highly efficient primary treatment for extensive-stage small cell lung cancer (ES-SCLC). However, patients receiving such treatment are prone to develop drug resistance. Local treatment is palliative and thus can alleviate the local symptoms and improve quality of life, but limited evidence is available for prolonging survival. Hence, this study evaluated the role of local treatment in chemotherapy of patients with ES-SCLC., Methods: A total of 302 ES-SCLC cases were enrolled in this retrospective study. Prognostic factors were analyzed by Kaplan-Meier and Cox multivariate proportional hazards model., Results: Median progression-free survival (PFS) and median survival time (MST) of the patients were 4.4 and 10.4 months, respectively. 1-, 2-, and 3-year survival rates were 37.8%, 10.2% and 4.4%, correspondingly. The MST of the primary tumor radiotherapy plus chemotherapy group was 14.3 months, whereas that of the chemotherapy group was 8.2 months (P<0.01). The MSTs of multiple-site, single-site, and non-metastasis local treatments were 18.7, 12.3 and 8.9 months, respectively (P<0.01). The MSTs of initiative, passive, and non-metastasis local treatments were 16.0, 10.9 and 9.4 months, correspondingly (P<0.01). The MSTs of patients with prophylactic cranial irradiation (PCI) and those without PCI were 19.8 and 9.9 months, respectively (P<0.01). Primary tumor radiotherapy, metastasis local treatment, and PCI were independent prognostic factors for ES-SCLC., Conclusions: Primary tumor radiotherapy, metastasis local treatment, and PCI can significantly improve survival in patients with ES-SCLC.
.

Background and Objective: Lung cancer is currently the leading cause of cancer death, two thirds of patients are over the age of 65. Small cell lung cancer (SCLC) accounts for about 15%-20% of all lung cancer. The objective of this study is to evaluate the survival of patients older than 65 with SCLC and analyze the independent prognostic factors in this group of patients., Methods: A retrospective study has enrolled 160 cases of lung cancer aged over 65. The prognostic factors were analyzed by Kaplan-Meier and Cox multivariate proportional hazards model., Results: ① The median follow-up time was 12 (2-109) months. 1-, 3-, and 5-year survival rate was 47.1%, 13.0%, 9.6% respectively, and 74.4%, 25.0%, 19.7% for limited-stage (LD), and 36.8%, 8.7%, 5.8% for extensive-stage (ED). Median survival time (MST) of all the patients was 12 months, 24 months for LD and 11 months for ED, respectively. ② Multivariate analysis suggested that performance status (PS) pre-treatment, the change of PS after treatment, stage, liver metastases and thoracic radiotherapy were the independent prognostic factors in all patients. ③ For LD-SCLC patients, PS pre-treatment, thoracic radiotherapy were the independent prognostic factors. The model of thoracic radiotherapy (concurrent chemoradiation vs sequential chemoradiation, early concurrent chemoradiation vs late concurrent chemoradiation) and prophylactic cranial irradiation (PCI) did not show significant difference. ④ For ED-SCLC patients, sex, the change of PS after treatment, chemotherapy, liver metastases, thoracic radiotherapy, PCI were the independent prognostic factors., Conclusions: The survival time is related to PS and thoracic radiotherapy in eldly patients. Besides, it is also related to sex, chemotherapy, liver metastases and PCI for ED-SCLC.

Background: Some clinical predictors can be used to evaluate the efficacy of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy for non-small cell lung cancer (NSCLC), including female, East-Asian, non-smoker, adenocarcinoma, skin rash, etc. The aim of this study is to explore the prognosis of advanced NSCLC patients treated with gefitinib for more than 6 months., Methods: Eighty advanced NSCLC patients treated with gefitinib for more than 6 months were collected from January, 2005 to March, 2010. The association of their clinical characteristics with median progression-free survival time (PFS) was analysed., Results: Significantly longer median PFS were found in patients with > 70 years old, earlier clinical stage (IIIb), non-bone metastasis (27 months vs 12 months; 32 months vs 12 months; 16 months vs 10 months, P < 0.05). There was no significant difference in median PFS between ECOG performance status 0-1 group and 2-4 group, between more than 4 cycles of chemotherapy and 1-4 cycles, between PFS of chemotherapy > 6 months group and ≤6 months group, however, ECOG 0-1 group and more than 4 cycles of chemotherapy or PFS of chemotherapy > 6 months group seemed to have longer median PFS (15 months vs 10 months; 16 months vs 12 months; 14 months vs 12 months). Compared with no skin rash and grade 0-I rash group, the patients with rash or grade ≥II rash had longer median PFS (16 months vs 13 months, P=0.171; 19 months vs 11 months, P=0.085). The median PFS was not related with sex, smoking index, pathological types, metastatic sites except bone, treatment strategy, etc (P > 0.05)., Conclusions: For gefitinib treatment, longer median PFS is likely to be obtained in patients with > 70 years old, earlier clinical stage (IIIb), non-bone metastasis.

As the largest bread basket in Zhejiang Province, Hangjiahu area is facing more and more serious water pollution, while the N loss loading by runoff from the paddy field during its submersed period is the main cause of the pollution. Through field experiment and fixed spot observation, the model of precipitation - runoff in Yangtze delta was testified, and the results showed that the precipitation - runoff model from HE Baogen was basically accorded with the fact after considering the impact of field overflow mouth, and the error was between - 19. 9% and + 18. 0%. The model of N concentration with precipitation - runoff in paddy field during submersed period was brought forward, with the R value being 0. 948. These two models consisted of the model of N loss loading by runoff from paddy field during submersed period. Based on this model as well as the past 30 years data of fertilization and precipitation, 1: 250,000 topography map, land use map, and water system map, the N loss loading and its distribution were estimated by using GIS method, and the results showed that the N loss loading was different from place to place, with an average of 35.26 kg N x hm(-2), and accounting for 12. 69% of the applied N. The N loss loading in Anji and Yuhang with obviously more precipitation was higher than that in other places, while Haining also had a serious N loss problem because of the huge amount of applied N.